Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,511 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Evaluation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986331, Placebo, Matching BMS-986331
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

NCT05411588
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-07275315, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
65
States / cities
Mobile, Alabama • Encino, California • Escondido, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Open-label Study of Liothyronine in MS

NCT02506751
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
liothyronine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 58 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Assessment of a Medication Reconciliation Program on Transitional Care

NCT00462059
View directory record Official record
Conditions
Hospitalization
Interventions
Treatment
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 22, 2026, 10:43 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

NCT04349280
View directory record Official record
Conditions
Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Lake Success, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

NCT06025396
View directory record Official record
Conditions
Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
Interventions
Cohort 1 - TMP-301, Placebo, Cohort 2 - TMP-301, Cohort 3 - TMP-301, Cohort 4 - TMP-301
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

NCT05806359
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danicamtiv, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 22, 2026, 10:43 AM EDT
Not listed No phase listed Observational

Evaluation of PatientToc in Community Pharmacies

NCT05235620
View directory record Official record
Conditions
Medication Adherence
Interventions
PatientToc use in pharmacies
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Rotator Cuff Healing Using a Nanofiber Scaffold in Patients Greater Than 55 Years

NCT04325789
View directory record Official record
Conditions
Rotator Cuff Tears, Full-thickness Rotator Cuff Tears
Interventions
nanofiber scaffold
Device
Lead sponsor
Atreon Orthopedics
Industry
Eligibility
55 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Fishers, Indiana • Saint Clair Shores, Michigan • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pazopanib in Renal Cell Carcinoma

NCT01361113
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Jul 22, 2026, 10:43 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

NCT01703260
View directory record Official record
Conditions
Nonalcoholic Steatohapatitis
Interventions
Roflumilast, Pioglitazone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Coronado, California • Annapolis, Maryland • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

NCT00000696
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-2a, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 22, 2026, 10:43 AM EDT
Withdrawn Phase 1 Interventional

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

NCT05828303
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
TPX-0005, Metformin Hydrochloride, Digoxin, Rosuvastatin Calcium
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jul 22, 2026, 10:43 AM EDT
Withdrawn Phase 2 Interventional

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT01504542
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
HS110 vaccine, Placebo
Biological
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia

NCT06056570
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
dotinurad, dotinurad + allopurinol, allopurinol
Drug
Lead sponsor
Urica Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries

NCT00773942
View directory record Official record
Conditions
Chronic Illness, Adverse Effects, Medication Errors, Elderly Patients
Interventions
Basic medication therapy management, Enhanced medication therapy management
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
65 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

NCT00434486
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine in Schizophrenia

NCT01104779
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Costa Mesa, California • Long Beach, California • Paramount, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 22, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

NCT07349394
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA, Rosuvastatin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 10:43 AM EDT